MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-29-2026
Abbott Laboratories Net Debt 2011-2026 | ABT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Abbott Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 B | 5.26 B | 6.95 B | 4.87 B | 7.74 B | 11.9 B | 14.3 B | 15.7 B | 18.5 B | 3.39 B | 4 B | 3.78 B | 3.09 B | 9.67 B | 8.6 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 B | 1.65 B | 7.96 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B |  USA |
 |
Avinger
AVGR
|
-12.4 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-77.2 M | - | - | $ 3.31 B | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 11.2 | 0.27 % | $ 317 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
347 M | $ 8.24 | 0.24 % | $ 1.24 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-26.7 M | $ 4.25 | -1.62 % | $ 159 M |  France |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
LENSAR
LNSR
|
-10.2 M | $ 5.88 | 1.38 % | $ 70.3 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.31 | 6.94 % | $ 50.9 M | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11 M | $ 0.47 | -0.57 % | $ 29.2 M | USA |
 |
MiMedx Group
MDXG
|
-148 M | $ 3.79 | 4.12 % | $ 560 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 18.5 | 1.48 % | $ 434 M | USA |
 |
LivaNova PLC
LIVN
|
-282 M | $ 73.71 | 1.08 % | $ 4.02 B |  Britain |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 11.23 | 3.5 % | $ 402 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-51 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.0 | -4.76 % | $ 16.9 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
Pulmonx Corporation
LUNG
|
-31.6 M | $ 1.54 | 14.93 % | $ 62.7 M | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 37.74 | -1.64 % | $ 319 M | USA |
 |
Myomo
MYO
|
-2.42 M | $ 0.91 | 4.17 % | $ 38.1 M | USA |
 |
Butterfly Network
BFLY
|
-130 M | $ 4.39 | 6.94 % | $ 1.08 B | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |
 |
Orthofix Medical
OFIX
|
78.5 M | $ 12.15 | 0.5 % | $ 481 M |  Curacao |
 |
Sintx Technologies
SINT
|
-898 K | $ 2.21 | 0.45 % | $ 6.13 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Profound Medical Corp.
PROF
|
-55 M | $ 6.92 | 2.82 % | $ 209 M | Canada |
 |
Globus Medical
GMED
|
-511 M | $ 84.03 | 5.13 % | $ 11.4 B | USA |
 |
Insulet Corporation
PODD
|
218 M | $ 156.59 | 1.28 % | $ 11 B | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 37.01 | 2.29 % | $ 1.15 B | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 44.14 | 3.79 % | $ 1.3 B | USA |
 |
TransMedics Group
TMDX
|
-32.3 M | $ 68.0 | 2.83 % | $ 2.31 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.18 B | $ 91.49 | 1.16 % | $ 3.18 B | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 82.97 | 0.99 % | $ 48.5 B | USA |